Dysregulated lipid metabolism blunts the sensitivity of cancer cells to EZH2 inhibitor

Zhang, TR; Guo, ZY; Huo, X; Gong, YQ; Li, C; Huang, JQ; Wang, Y; Feng, H; Ma, XJ; Jiang, CT; Yin, QQ; Xue, LX

Yin, QQ; Xue, LX (通讯作者)，Peking Univ, Hosp 3, Ctr Basic Med Res, Inst Med Innovat & Res, 49 North Garden Rd, Beijing 100191, Peoples R China.

EBIOMEDICINE, 2022; 77 ():

Abstract

Background Sensitivity has been a key issue for Enhancer of zeste homolog 2 (EZH2) inhibitors in cancer therapy. The EZH2 inhibitor EPZ-6438 was first......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索